Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
2.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group..

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
3.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912.

PMID:
23569311
4.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR; TRIO 010 investigators..

Lancet Oncol. 2011 Apr;12(4):369-76. doi: 10.1016/S1470-2045(11)70037-7. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

PMID:
21429799
5.

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Wang X, Huang C, Li M, Gu Y, Cui Y, Li Y.

Tumour Biol. 2014 May;35(5):4841-8. doi: 10.1007/s13277-014-1635-4.

PMID:
24570182
6.

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.

Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S.

Breast Cancer Res Treat. 2011 Oct;129(3):829-38. doi: 10.1007/s10549-011-1685-x.

PMID:
21805309
7.

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

Schwartzberg LS, Badarinath S, Keaton MR, Childs BH.

Clin Breast Cancer. 2014 Jun;14(3):161-8. doi: 10.1016/j.clbc.2013.12.003.

PMID:
24566467
8.

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.

Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris HA 3rd, Hainsworth JD.

Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5.

PMID:
26456573
10.
11.

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.

Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO)..

J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1.

PMID:
23463098
12.

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M.

Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008.

PMID:
22520733
13.

Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.

Refaat T, Choi M, Gaber G, Kiel K, Mehta M, Gradishar W, Small W Jr.

Am J Clin Oncol. 2014 Oct;37(5):480-5. doi: 10.1097/COC.0b013e31827e4e9a.

PMID:
23388565
14.

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ.

J Korean Med Sci. 2009 Oct;24(5):910-7. doi: 10.3346/jkms.2009.24.5.910.

15.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.

Palumbo R, Sottotetti F, Trifirò G, Piazza E, Ferzi A, Gambaro A, Spinapolice EG, Pozzi E, Tagliaferri B, Teragni C, Bernardo A.

Drug Des Devel Ther. 2015 Apr 15;9:2189-99. doi: 10.2147/DDDT.S79563.

16.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F.

BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.

17.

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.

Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, Broadwater G, Blackwell K.

Clin Breast Cancer. 2013 Dec;13(6):416-20. doi: 10.1016/j.clbc.2013.08.003.

PMID:
24099649
18.

First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.

Dank M, Budi L, Piko B, Mangel L, Erfan J, Cseh J, Ruzsa A, Landherr L.

Anticancer Res. 2014 Mar;34(3):1275-80.

PMID:
24596372
19.

First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.

Schneeweiss A, Förster F, Tesch H, Aktas B, Gluz O, Geberth M, Hertz-Eichenrode MM, Schönegg W, Schumacher C, Kutscheidt A, Kiewitz C, Klawitter S, Schmidt M.

Anticancer Res. 2016 Mar;36(3):967-74.

PMID:
26976985
20.

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, Hurley E, Hurley J, Reis I, Richman S, Seo P, Silva O, Slingerland J, Tukia K, Welsh C, Glück S.

Breast Cancer Res Treat. 2010 Sep;123(2):427-35. doi: 10.1007/s10549-010-1002-0.

PMID:
20585851
Items per page

Supplemental Content

Support Center